26-Country Survey Maps Wide Gaps in Neurotechnology Oversight

A survey spanning 26 countries has exposed substantial gaps in the rules governing who may record, decode and modulate human brain activity. The review, highlighted by Bioengineer.org under the headline "Who Can Touch Your Brain? 26-Country Survey Exposes Gaps in Neurotechnology Rules," examined how national legal frameworks handle neurotechnologies — devices and systems that interface with the nervous system, from scalp EEG (electroencephalography, the recording of the brain's electrical activity through electrodes on the scalp) to implanted brain-computer interfaces.

The core finding is jurisdictional fragmentation. The 26 countries surveyed approach neurotechnology oversight through markedly different legal instruments, leaving large territories of brain-data practice effectively unregulated. For clinical neurophysiology laboratories and epilepsy monitoring units, the finding lands close to home: the same scalp EEG and intracranial recordings (electrodes placed inside the skull, used in presurgical epilepsy evaluation) that routinely inform clinical decisions also generate data whose long-term ownership, storage and secondary use remain legally ambiguous in much of the world.

Why does a 26-country survey matter now?

Neurotechnology has moved past the research bench. Consumer-grade EEG headsets, neurofeedback systems (real-time display of brain activity used to train self-regulation) and investigational brain-computer interfaces — devices that translate neural signals into commands for computers or prostheses — now sit at very different points on the regulatory spectrum. Some carry regulatory clearance for clinical or consumer use; others remain investigational, running under research protocols with their own, often lighter, oversight.

The survey's central concern is that this spectrum is not mapped consistently across borders. A device that one regulator treats as a medical instrument requiring clinical validation, another may treat as a wellness product with no clinical claims to answer for. For readers in the reading room, the practical stakes are concrete: EEG and related neurophysiological data are increasingly collected outside clinical settings, by devices and operators that no neurology board oversees, and the resulting records can re-enter clinical contexts without a clear legal chain of custody.

The provocative framing of the original report — "Who can touch your brain?" — points at a question most existing statutes cannot answer. Traditional medical-device regulation covers safety and efficacy of hardware. It does not, in most jurisdictions, define who owns neural data, who may decode it, or what consent covers when brain recordings are reused for purposes far from the original acquisition.

What does this mean for clinical practice?

For neurophysiology teams, the survey's implications translate into three operating realities:

• Data provenance is becoming a clinical question, not only a legal one. When EEG or ECoG (electrocorticography, recordings from electrodes placed directly on the cortical surface) data arrives from external sources, its acquisition standards and consent basis may be unverifiable.
• Cross-border collaboration — increasingly common in epilepsy surgery planning and BCI research — now involves jurisdictions with incompatible definitions of neural data protection.
• Institutional review boards and hospital legal teams face questions that national law has not yet settled, particularly around secondary use of archived recordings.

The survey's breadth — 26 countries — is itself part of the message. Single-nation analyses of neurotechnology governance exist; a comparative frame makes the gaps visible. What one country regulates as protected health information linked to a person's brain activity, another may leave in the same category as fitness-tracker output.

Where does oversight go from here?

The gaps the survey documents are not static. Implanted and non-invasive neurotechnologies continue to advance, and every new recording modality — high-density scalp EEG, MEG (magnetoencephalography, which measures the magnetic fields of brain activity), intracranial arrays — widens the volume of neural data that existing frameworks were never designed to govern. The survey's implicit argument is that regulation built for conventional medical devices cannot, on its own, answer questions about mental privacy, data ownership and consent in neurotechnology.

For clinicians and researchers, the near-term task is practical: document consent scope for neural data explicitly, track the regulatory status of every device used — FDA-cleared (cleared by the U.S. Food and Drug Administration) versus investigational — and treat cross-border data-sharing agreements as unresolved legal terrain rather than routine logistics. The survey suggests that until national frameworks converge, the burden of protecting neural data will fall on the institutions that collect it, and the coming years will test whether self-regulation can hold the line that 26 countries' laws currently leave open.